Risk-based response-adapted Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children adolescents and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation.
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL).
Description
The purpose of this study is to test the effectiveness, safety, and tolerability of an investigational drug called nivolumab in children, adolescents, and young adults with classic Hodgkin Lymphoma (CHL) in combination with brentuximab vedotin.
Details
| Condition | Hodgkin Disease |
|---|---|
| Age | 5years - 30years |
| Clinical Study Identifier | TX7900 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.